Search tool

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership. The newsletter aims to offer a complete overview of the work of the Agency and...

Drug use remains a key issue within Europe, and the EU’s response to drug use has a profound impact on the health, well-being and security of its citizens. The use of illicit...

The report outlines the results of the implementation of the Council Decision in 2005 and describes some issues arising from the initial experiences. In 2005, 14 new psychoactive substances were officially notified...

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership. The newsletter aims to offer a complete overview of the work of the Agency and...

The adoption, in 2005, by the European Council, of a new legal instrument to deal with the emergence of new substances on the European drug scene, spurred the EMCDDA to issue its...

Commissioned each year by the EMCDDA and produced by the national focal points of the Reitox network, the National reports draw an overall picture of the drug phenomenon at national level in...

Commissioned each year by the EMCDDA and produced by the National focal points of the Reitox network, the National reports draw an overall picture of the drug phenomenon at national level in...

The 2006 EMCDDA work programme completes the implementation of the three-year work programme for 2004–06 and is consistent with its principal objectives. It takes into account the objectives of the EU drugs...

The EMCDDA receives stable funding under Commission budget line B3-441 of the general budget of the European Union. Each year, a preliminary draft budget is presented by the Centre's Director to the...

Drugnet Europe, the EMCDDA's quarterly newsletter, provides regular information on the Agency's activities to a broad readership. The newsletter aims to offer a complete overview of the work of the Agency and...